Please login to the form below

Not currently logged in
Email:
Password:

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

Novartis buys CellforCure to bolster cell, gene therapy

Novartis buys CellforCure to bolster cell, gene therapy

and adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Latest news

  • CAR-Ts take centre stage as ASH18 comes to a close CAR-Ts take centre stage as ASH18 comes to a close

    Similarly, CAR-T pioneer Novartis reported longer-term data on Kymriah (tisagenlecleucel) in children with r/r ALL and adults with r/r diffuse large B-cell lymphoma (DLBCL) that it ... Longer-term follow-up from the JULIET study in DLBCL found a 64%

  • Gilead strikes deal with NHS England on CAR-T Yescarta Gilead strikes deal with NHS England on CAR-T Yescarta

    Today’s agreement will see around 200 adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma be eligible for treatment. ... Not far behind Yescarta in the NICE process in DLBCL is Novartis’ Kymriah.

  • Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

    We were surprised that NICE have not supported the “end of life” criteria for this population of DLBCL patients and strongly disagree with this decision. ... population in Europe, which could give Gilead space to establish itself in DLBCL in these

  • Gilead optimistic about Yescarta deal in UK Gilead optimistic about Yescarta deal in UK

    The CAR-T production process. DLBCL will be the competitive battleground for Novartis and Gilead, and there’s no doubt Yescarta has the upper hand at this early stage. ... It has significantly better response rates in DLBCL than Kymriah: its overall

  • Novartis’ CAR-T Kymriah gets green light in England Novartis’ CAR-T Kymriah gets green light in England

    Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population. ... That might suggest Novartis will have a tougher time when it comes to the adult DLBCL indication for Kymriah.

More from news
Approximately 6 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics